



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Laparoscopic and Percutaneous Techniques for the Myolysis of Uterine Fibroids

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 244

BCBSA Reference Number: 4.01.19

NCD/LCD: N/A

Related Policies

- MRI-Guided Focused Ultrasound for the Treatment of Uterine Fibroids and Other Tumors, #[243](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Laparoscopic and percutaneous techniques of myolysis as a treatment of uterine fibroids is **INVESTIGATIONAL**.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.
Medicare HMO Blue SM	This is not a covered service.
Medicare PPO Blue SM	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

CPT codes:	Code Description
58674	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency

ICD Diagnosis Codes

Investigational for all diagnoses.

Description

UTERINE FIBROIDS

Uterine fibroids, also known as leiomyomas, are among the most common conditions affecting women in their reproductive years; symptoms include menorrhagia, pelvic pressure, or pain.

Treatment

Surgery, including hysterectomy and various myomectomy procedures, is considered the criterion standard for symptom resolution. However, there is the potential for surgical complications and, in the case of a hysterectomy, the uterus is not preserved. In addition, multiple myomectomy may be associated with longer operating time, postoperative febrile morbidity, and development of pelvic adhesions. There has been long-standing research interest in developing minimally invasive alternatives for treating uterine fibroids, including procedures that retain the uterus and permit future childbearing. Treatment options include uterine artery embolization (see MP #242) and the transcutaneous magnetic resonance imaging-guided focused ultrasound therapy (see MP #243). Various techniques to induce myolysis have also been studied including Nd:YAG lasers, bipolar electrodes, cryomyolysis, and radiofrequency ablation. With these techniques, an energy source is used to create areas of necrosis within uterine fibroids, reducing their volume and thus relieving symptoms. Early methods involved multiple insertions of probes into the fibroid, performed without imaging guidance. There were concerns about serosal injury and abdominopelvic adhesions with these techniques, possibly due to the multiple passes through the serosa needed to treat a single fibroid.¹ Newer systems using radiofrequency energy do not require repetitive insertions of needle electrodes. Ultrasonography is used laparoscopically to determine the size and location of fibroids, to guide the probe, and to ensure the probe is in the correct location so that optimal energy is applied to the fibroid. Percutaneous approaches using magnetic resonance imaging guidance have also been reported.

Summary

For individuals who have symptomatic uterine fibroids who receive RFVTA, the evidence includes an RCT and systematic review. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The meta-analysis found low rates of reintervention with RFVTA and quality of life outcomes that were similar to uterine artery embolization and myomectomy at 12 months. Data on reintervention rates at 36 months were limited to 1 study and no studies reported reintervention rates at 60 months. The single RCT with a follow-up longer than 3 months found that RFVTA was noninferior to laparoscopic myomectomy on the trial's primary outcome: length of hospitalization. A number of secondary outcomes were reported at 12 and 24 months, including symptoms and quality of life. None of the secondary outcomes demonstrated significant between-group differences in a subgroup analysis of 43 patients. Additional well-designed RCTs with longer follow-up are needed to determine the effect of RFVTA on health outcomes compared with other treatment options. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have symptomatic uterine fibroids who receive laser or bipolar needles, the evidence includes case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The case series were published in the 1990s, and the procedures used then may not reflect current practice. RCTs comparing laser or bipolar needles with alternative treatments for uterine fibroids are needed to evaluate the safety and efficacy of this technology adequately. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have symptomatic uterine fibroids who receive cryomyolysis, the evidence includes case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. Among the few case series, sample sizes were small (≤ 20 patients). RCTs comparing cryomyolysis with alternative treatments for uterine fibroids are needed to evaluate the safety and efficacy of this technology adequately. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have symptomatic uterine fibroids who receive magnetic resonance imaging-guided laser ablation, the evidence includes a study with historical controls. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. A single study with historical controls is not sufficiently robust to evaluate this technology. RCTs comparing magnetic resonance imaging-guided laser ablation with alternative treatments for uterine fibroids are needed to evaluate safety and efficacy adequately. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
10/2018	BCBSA National medical policy review. No changes to policy statements. New references added. Background and summary clarified.
9/2017	New references added from BCBSA National medical policy.
1/2017	Clarified coding information for the 2017 code changes.
10/2016	New references added from BCBSA National medical policy.
8/2015	New references added from BCBSA National medical policy.
9/2014	New references added from BCBSA National medical policy.
6/2014	Coding information clarified.
10/2013	New references from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
9/2011	Reviewed - Medical Policy Group - Urology, Obstetrics and Gynecology. No changes to policy statements.
10/2010	Reviewed - Medical Policy Group - Obstetrics and Gynecology. No changes to policy statements.
7/2010	Medical Policy 244 effective 7/10 describing on-going non-coverage

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Jones S, O'Donovan P, Toub D. Radiofrequency ablation for treatment of symptomatic uterine fibroids. *Obstet Gynecol Int.* Oct 2012;2012:194839. PMID 21961009
2. Sandberg EM, Tummers F, Cohen SL, et al. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis. *Fertil Steril.* Apr 2018;109(4):698-707 e691. PMID 29653718

3. Brucker SY, Hahn M, Kraemer D, et al. Laparoscopic radiofrequency volumetric thermal ablation of fibroids versus laparoscopic myomectomy. *Int J Gynaecol Obstet*. Jun 2014;125(3):261-265. PMID 24698202
4. Kramer B, Hahn M, Taran FA, et al. Interim analysis of a randomized controlled trial comparing laparoscopic radiofrequency volumetric thermal ablation of uterine fibroids with laparoscopic myomectomy. *Int J Gynaecol Obstet*. May 2016;133(2):206-211. PMID 26892690
5. Hahn M, Brucker S, Kraemer D, et al. Radiofrequency volumetric thermal ablation of fibroids and laparoscopic myomectomy: long-term follow-up from a randomized trial. *Geburtshilfe Frauenheilkd*. May 2015;75(5):442-449. PMID 26097247
6. Keltz J, Levie M, Chudnoff S. Pregnancy outcomes after direct uterine myoma thermal ablation: review of the literature. *J Minim Invasive Gynecol*. May - Jun 2017;24(4):538-545. PMID 28109894
7. Goldfarb HA. Bipolar laparoscopic needles for myoma coagulation. *J Am Assoc Gynecol Laparosc*. Feb 1995;2(2):175-179. PMID 9050553
8. Goldfarb HA. Nd:YAG laser laparoscopic coagulation of symptomatic myomas. *J Reprod Med*. Jul 1992;37(7):636-638. PMID 1387912
9. Nisolle M, Smets M, Malvaux V, et al. Laparoscopic myolysis with the Nd:YAG laser. *J Gynecol Surg*. Summer 1993;9(2):95-99. PMID 10171973
10. Donnez J, Squifflet J, Polet R, et al. Laparoscopic myolysis. *Hum Reprod Update*. Nov-Dec 2000;6(6):609-613. PMID 11129695
11. Phillips DR, Nathanson HG, Milim SJ, et al. Laparoscopic leiomyoma coagulation. *J Am Assoc Gynecol Laparosc*. Aug 1996;3(4 Suppl):S39. PMID 9074213
12. Zreik TG, Rutherford TJ, Palter SF, et al. Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids. *J Am Assoc Gynecol Laparosc*. Feb 1998;5(1):33-38. PMID 9454874
13. Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: a possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. *Am J Obstet Gynecol*. Mar 2004;190(3):639-643. PMID 15041993
14. Zupi E, Marconi D, Sbracia M, et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: one-year follow up. *J Minim Invasive Gynecol*. Jul-Aug 2005;12(4):343-346. PMID 16036195
15. Hindley JT, Law PA, Hickey M, et al. Clinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids. *Hum Reprod*. Oct 2002;17(10):2737-2741. PMID 12351555
16. American College of Obstetricians Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. *Obstet Gynecol*. Aug 2008;112(2 Pt 1):387-400. PMID 18669742
17. American College of Obstetricians and Gynecologists (ACOG). Alternatives to hysterectomy in the management of leiomyomas. ACOG practice bulletin No. 96. 2016; <http://www.acog.org/-/media/List-of-Titles/PBListOfTitles.pdf>. Accessed July 23, 2018.